JP2024521919A5 - - Google Patents
Info
- Publication number
- JP2024521919A5 JP2024521919A5 JP2023574587A JP2023574587A JP2024521919A5 JP 2024521919 A5 JP2024521919 A5 JP 2024521919A5 JP 2023574587 A JP2023574587 A JP 2023574587A JP 2023574587 A JP2023574587 A JP 2023574587A JP 2024521919 A5 JP2024521919 A5 JP 2024521919A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163202272P | 2021-06-03 | 2021-06-03 | |
| US63/202,272 | 2021-06-03 | ||
| US202163282588P | 2021-11-23 | 2021-11-23 | |
| US63/282,588 | 2021-11-23 | ||
| PCT/IB2022/055168 WO2022254377A1 (en) | 2021-06-03 | 2022-06-02 | Neodegrader-anti-cd33 antibody conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521919A JP2024521919A (ja) | 2024-06-04 |
| JP2024521919A5 true JP2024521919A5 (enExample) | 2025-06-09 |
Family
ID=84323935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574587A Pending JP2024521919A (ja) | 2021-06-03 | 2022-06-02 | ネオデグラダー－抗ｃｄ３３抗体コンジュゲート |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240252671A1 (enExample) |
| EP (1) | EP4346910A4 (enExample) |
| JP (1) | JP2024521919A (enExample) |
| KR (1) | KR20240042598A (enExample) |
| AU (1) | AU2022284372A1 (enExample) |
| CA (1) | CA3222185A1 (enExample) |
| CL (2) | CL2023003605A1 (enExample) |
| CO (1) | CO2023016712A2 (enExample) |
| IL (1) | IL308812A (enExample) |
| MX (1) | MX2023014282A (enExample) |
| PE (1) | PE20250159A1 (enExample) |
| WO (1) | WO2022254377A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250090681A1 (en) * | 2021-06-03 | 2025-03-20 | Orum Therapeutics, Inc. | Neodegrader conjugates |
| EP4527415A1 (en) * | 2022-05-18 | 2025-03-26 | Medilink Therapeutics (Suzhou) Co., Ltd. | Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof |
| KR20250133786A (ko) * | 2023-02-15 | 2025-09-08 | 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. | 도마이드계 분자 접착제 유도체 및 이의 용도 |
| WO2024222841A1 (zh) * | 2023-04-27 | 2024-10-31 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物 |
| WO2024249235A1 (en) * | 2023-06-01 | 2024-12-05 | Abbvie Inc. | Anti-human cd33 bet degrader antibody-drug conjugates |
| CN122422333A (zh) * | 2023-10-17 | 2026-07-17 | 百时美施贵宝公司 | Gspt1降解化合物、抗cd33抗体和抗体-药物缀合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5238936B2 (ja) * | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| CA2957226C (en) * | 2008-10-29 | 2018-08-14 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer |
| KR101870555B1 (ko) * | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| PL2822575T3 (pl) * | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
| US20180312561A1 (en) * | 2015-06-12 | 2018-11-01 | Immungene, Inc. | Focused interferon immunotherapy for treatment of cancer |
| CN104994263B (zh) * | 2015-06-30 | 2016-12-28 | 广东欧珀移动通信有限公司 | 一种摄像装置及具有该摄像装置的终端 |
| CN109152843A (zh) * | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| US20230338564A1 (en) * | 2020-03-31 | 2023-10-26 | Orum Therapeutics, Inc. | Neodegrader conjugates |
-
2022
- 2022-06-02 AU AU2022284372A patent/AU2022284372A1/en active Pending
- 2022-06-02 CA CA3222185A patent/CA3222185A1/en active Pending
- 2022-06-02 IL IL308812A patent/IL308812A/en unknown
- 2022-06-02 MX MX2023014282A patent/MX2023014282A/es unknown
- 2022-06-02 WO PCT/IB2022/055168 patent/WO2022254377A1/en not_active Ceased
- 2022-06-02 US US18/566,805 patent/US20240252671A1/en active Pending
- 2022-06-02 JP JP2023574587A patent/JP2024521919A/ja active Pending
- 2022-06-02 EP EP22815474.6A patent/EP4346910A4/en active Pending
- 2022-06-02 PE PE2023003198A patent/PE20250159A1/es unknown
- 2022-06-02 KR KR1020247000100A patent/KR20240042598A/ko active Pending
-
2023
- 2023-12-01 CO CONC2023/0016712A patent/CO2023016712A2/es unknown
- 2023-12-01 CL CL2023003605A patent/CL2023003605A1/es unknown
-
2026
- 2026-02-10 CL CL2026000399A patent/CL2026000399A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024059609A5 (enExample) | ||
| JP2024521921A5 (enExample) | ||
| AU2026202052B2 (en) | Anti-c-Met antibody drug conjugates | |
| JP2022537158A5 (enExample) | ||
| TW202400137A (zh) | 喜樹鹼偶聯物 | |
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| WO2023206350A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| TW202400245A (zh) | 抗體藥物偶聯物及其製備方法和用途 | |
| JP2013505946A5 (enExample) | ||
| JP2020525542A5 (enExample) | ||
| JP7846634B2 (ja) | 抗体－免疫賦活化剤コンジュゲートの新規製造方法 | |
| CN112153987B (zh) | 抗体-药物缀合物及其用于治疗癌症的用途 | |
| JP2017186337A5 (enExample) | ||
| JP2022534297A (ja) | 抗ｂ７－ｈ３抗体 | |
| JP2012522513A5 (enExample) | ||
| JP2017506234A5 (enExample) | ||
| JP2022512401A5 (enExample) | ||
| JP2011500725A5 (enExample) | ||
| JP2022543231A5 (enExample) | ||
| JP2017506630A5 (enExample) | ||
| JPWO2021177438A5 (enExample) | ||
| JP2016512223A5 (enExample) | ||
| EP3999118A1 (en) | Antibody-sting agonist conjugates and their use in immunotherapy | |
| JP2022510505A5 (enExample) | ||
| RU2018102358A (ru) | Нацеленные конъюгаты ksp ингибиторов |